A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.

Maria Cristina Pirosa,Lu Zhang,Felicitas Hitz,Urban Novak,Dagmar Hess,Tatiana Terrot,Mariarosa Pascale,Luca Mazzucchelli,Francesco Bertoni,Franco Cavalli,Emanuele Zucca,Anastasios Stathis

A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.

2021

Maria Cristina Pirosa
Lu Zhang
Felicitas Hitz
Urban Novak
Dagmar Hess
Tatiana Terrot
Mariarosa Pascale
Luca Mazzucchelli
Francesco Bertoni
Franco Cavalli
Emanuele Zucca
Anastasios Stathis

This phase I trial evaluated the safety, tolerability, and preliminary activity of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed/refractory CD22 positive B-cell n...

Keywords:

Inotuzumab ozogamicin
CD22
Oncology
in patient
Internal medicine
Tolerability
Refractory
Medicine
Temsirolimus
B cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations